Veracyte's significant beat on both EPS and sales estimates for Q1 2024, coupled with a substantial year-over-year sales increase, suggests a strong financial performance and operational efficiency. This outperformance is likely to instill investor confidence and could lead to a positive short-term impact on VCYT's stock price, as it demonstrates the company's ability to exceed analyst expectations and maintain growth.